OSE Immunotherapeutics SA (EPA:OSE)
France
· Delayed Price · Currency is EUR | Market Cap | 96.63M |
| Revenue (ttm) | 1.78M |
| Net Income (ttm) | -32.52M |
| Shares Out | 22.42M |
| EPS (ttm) | -1.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 261,196 |
| Average Volume | 89,917 |
| Open | 4.496 |
| Previous Close | 4.430 |
| Day's Range | 4.300 - 4.730 |
| 52-Week Range | 4.152 - 7.700 |
| Beta | 0.51 |
| RSI | 39.66 |
| Earnings Date | Mar 27, 2026 |
About OSE Immunotherapeutics
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]
Financial Performance
Financial StatementsNews
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationale Chronic Pouchitis offers a...
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) Nantes, France, January 21, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE),...
OSE Immunotherapeutics SA (ORPOF) Discusses Strategic Plan With Four Opportunities for Value Creation Transcript
OSE Immunotherapeutics Unveils 2026-2028 Strategic Plan With Four Value-Creating Opportunities
(RTTNews) - OSE Immunotherapeutics (OSE) has announced a new three-year strategic plan to accelerate late-stage programs while maintaining financial discipline.
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics' Role in ABBV-230 Development While Preserving ...
OSE Immunotherapeutics (ORPOF) Appoints Interim CEO Marc Le Bozec
OSE Immunotherapeutics (ORPOF) Appoints Interim CEO Marc Le Bozec
OSE Immunotherapeutics replaces CEO Nicolas Poirier, appoints Marc Le Bozec as interim CEO
OSE Immunotherapeutics SA (ORPOF) Shareholder/Analyst Call Transcript
OSE Immunotherapeutics SA (OTC:ORPOF) Shareholder/Analyst Call September 18, 2025 12:00 PM EDTCompany ParticipantsFiona Olivier - Chief Corporate Affairs...